Navigation Links
Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
Date:11/19/2007

SAN DIEGO, Nov. 19 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Jorgine Ellerbrock has joined the Company as senior vice president, operations.

"We are pleased to add Jorgine's extensive experience in operations and supply chain management to our already strong senior management team," said Carl Hull, Gen-Probe's executive vice president and chief operating officer.

Ms. Ellerbrock, 46, joins the Company from Invitrogen Corporation, where she had been vice president, operations, since 2004, most recently for the Molecular Biology Business. Prior to joining Invitrogen, she held positions of increasing responsibility with GE Healthcare Bio-Sciences (formerly Amersham Biosciences). She served as vice president, operations from 2002 to 2004, and vice president, genomics product management, in 2002. Before joining Amersham in 1998, Ms. Ellerbrock was employed by Roche Molecular Systems and Gen-Probe. She earned a BS in microbiology and an MBA from San Diego State University.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include, but are not limited to, the risk that we cannot retain key executives. The foregoing sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Senior director, investor relations and corporate communications

858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
4. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
5. Nick Childs Joins Grey New York as Director of Content Development
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
8. NASN Joins Partnership to Fight Chronic Disease
9. AstraZeneca Joins Local Walking Movement
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Fund Manager Joins Board of GSI Securitization Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs ... friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , “Choosing ... Coats and Dr. David Coats. In September of 1983, they flew to Haiti ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... phenomenon is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the ... Creation,” a Christian-based talk show located in Michigan. , “We need to partner ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women who want ... suggests that autologous fat grafting—taking one’s own fat and putting it in other ... , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
(Date:1/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The interventional radiology products market is expected to reach ... at a CAGR of 4.8%. This market is segmented based on ... the growth of this market are rising incidence of chronic diseases, ...
Breaking Medicine Technology: